MX2022010512A - Inhibidores de proteína bcl-2. - Google Patents

Inhibidores de proteína bcl-2.

Info

Publication number
MX2022010512A
MX2022010512A MX2022010512A MX2022010512A MX2022010512A MX 2022010512 A MX2022010512 A MX 2022010512A MX 2022010512 A MX2022010512 A MX 2022010512A MX 2022010512 A MX2022010512 A MX 2022010512A MX 2022010512 A MX2022010512 A MX 2022010512A
Authority
MX
Mexico
Prior art keywords
bcl
protein inhibitors
formula
various
tumors
Prior art date
Application number
MX2022010512A
Other languages
English (en)
Inventor
Peter Qinhua Huang
Kevin Duane Bunker
Joseph Robert Pinchman
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2022010512A publication Critical patent/MX2022010512A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen varios inhibidores de la proteína Bcl-2, junto con métodos para usarlos para tratar afecciones caracterizadas por una proliferación celular excesiva, tales como cáncer y tumores. En varias modalidades, los inhibidores de la proteína Bcl-2 son compuestos o sales farmacéuticamente aceptables de la siguiente Fórmula (I), donde las variables en la Fórmula (I) se definen en la presente descripción. (I).
MX2022010512A 2020-04-28 2021-04-26 Inhibidores de proteína bcl-2. MX2022010512A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063016760P 2020-04-28 2020-04-28
PCT/US2021/029181 WO2021222114A1 (en) 2020-04-28 2021-04-26 Bcl-2 protein inhibitors

Publications (1)

Publication Number Publication Date
MX2022010512A true MX2022010512A (es) 2022-11-16

Family

ID=78332399

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010512A MX2022010512A (es) 2020-04-28 2021-04-26 Inhibidores de proteína bcl-2.

Country Status (12)

Country Link
US (1) US20230167105A1 (es)
EP (1) EP4107152A4 (es)
JP (1) JP2023524439A (es)
KR (1) KR20230002483A (es)
CN (1) CN115461335A (es)
AU (1) AU2021263568A1 (es)
BR (1) BR112022021910A2 (es)
CA (1) CA3173843A1 (es)
IL (1) IL297586A (es)
MX (1) MX2022010512A (es)
TW (1) TW202206424A (es)
WO (1) WO2021222114A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020310147A1 (en) * 2019-07-10 2022-01-06 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
AU2023264537A1 (en) 2022-05-06 2024-11-14 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
EP4519260A1 (en) 2022-05-06 2025-03-12 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xdegraders
PE20250007A1 (es) 2022-05-06 2025-01-07 Treeline Biosciences Inc Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina
US20260092057A1 (en) * 2022-05-12 2026-04-02 Kymera Therapeutics, Inc. Bcl-xl/bcl-2 degraders and uses thereof
WO2024078581A1 (en) * 2022-10-12 2024-04-18 Appicine Therapeutics (Hk) Limited Selective bcl-xl protac compounds and uses thereof
WO2024179577A1 (zh) * 2023-03-01 2024-09-06 西藏海思科制药有限公司 一种Bcl-2家族蛋白降解剂的药物组合物
KR20260111020A (ko) 2023-11-07 2026-07-14 트리라인 바이오사이언시스, 인크. 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제
AU2024378690A1 (en) 2023-11-07 2026-05-07 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
IL327973A (en) 2023-11-07 2026-06-01 Treeline Biosciences Inc Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
IL316472A (en) * 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
ES3041854T3 (en) * 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
AU2020310147A1 (en) * 2019-07-10 2022-01-06 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors

Also Published As

Publication number Publication date
EP4107152A4 (en) 2023-07-26
CA3173843A1 (en) 2021-11-04
IL297586A (en) 2022-12-01
US20230167105A1 (en) 2023-06-01
CN115461335A (zh) 2022-12-09
EP4107152A1 (en) 2022-12-28
JP2023524439A (ja) 2023-06-12
BR112022021910A2 (pt) 2022-12-13
WO2021222114A1 (en) 2021-11-04
TW202206424A (zh) 2022-02-16
KR20230002483A (ko) 2023-01-05
AU2021263568A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
MX2022000310A (es) Inhibidores de proteina bcl-2.
MX2024000357A (es) Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
PH12022552739A1 (en) Fused tricyclic kras inhibitors
MX2025013001A (es) Inhibidores espiro-heterocíclicos de las proteínas mutantes kras g12c y usos de los mismos.
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
MX2025003821A (es) Compuestos con actividad contra tumores mutantes de kras
MX2023009185A (es) Compuestos de benzamida.
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
BR112022021910A2 (pt) Inibidores da proteína bcl-2
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MX2023004373A (es) Metodos y composiciones para la degradacion dirigida de proteinas.
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2024013215A (es) Compuestos para inhibir kif18a
MX2024002391A (es) Inhibidores de indolina de kif18a.
WO2024006292A3 (en) Methods of treating cancer
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
CR20220548A (es) Compuestos de azalactama como inhibidores de hpk1
PH12022550078A1 (en) Enzyme inhibitors
WO2024163641A3 (en) Formulations for treating cancer
MX2024013787A (es) Inhibidores de menina-mll para el tratamiento de cáncer.
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2